HypoIntense & HyperIntense Lesions
On Magnetic Resonance Imaging
In Secondary/Progressive MS

Adams H, Wagner S, Sobel DF, Slivka LS, Sipe JC, Romine JS, Beutler E, Koziol JA
Eur Neurol 1999 Jul;42(1):52-63
The Scripps Research Institute, Dept of Molecular and Experimental Medicine, La Jolla, Calif., USA
PMID# 10394049

Cranial Magnetic Resonance Imaging (MRI) is widely used to monitor disease activity in clinical trials in Multiple Sclerosis (MS).

The purpose of this study is to examine Lesion Burden as determined from HypoIntense regions on postcontrast T1-weighted scans (or black holes), and lesion burden on conventional T2-weighted scans.

From a cohort of Secondary/Progressive MS patients who participated in a placebo-controlled, randomized, double-blind cross-over trial assessing the therapeutic efficacy of Cladribine.

T2 lesion volumes and black hole volumes are approximately normal distributed when log-transformed, and are highly correlated (adjusted R2 = 0.63).

Changes in clinical scores could be predicted with a reasonable degree of precision from baseline scores and changes in T2 lesion volumes (adjusted R2 values = 0.52-0.7).

Stratification schemes for clinical trials should include:

  1. The acute proportion of the disease
  2. Degree of permanent damage (Black Holes)
  3. T2 Lesion Volume

Medical Texts
Anatomy | Immune System | Lymphocytes | Meds
MHC | Movement | Cranial Nerves | Physiology

MS Glossary ThJuland's MSers' Glen - Our CyberHome Page Top The Glen's Gallery: Come & Share Our Stories MS Files MS Abstracts Site Index

ANS | Bladder | Cognition | Fatigue | Fluid | Genetics
Interferons | IVIG | Nitric Oxide | Optic Neuritis | Pain
Physiology | Prions | Prognosis | ReMyelinate | Steroids
Stress | Treatments | TNF | Uric Acid | Viruses

Copyright 1997 - 2010:
Permission is granted to MS Societies and all MSers to utilize information from these pages provided that no financial reward is gained and attribution is given to the author/s.